Laropiprant
- Generic Name
- Laropiprant
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClFNO4S
- CAS Number
- 571170-77-9
- Unique Ingredient Identifier
- G7N11T8O78
- Background
Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.
A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT01451619
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
Phase 1
Completed
- Conditions
- Primary HypercholesterolemiaMixed Hyperlipidemia
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01012219
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
Phase 1
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT00769132
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT00618995
MK0524A Phase IIb Study (0524A-011)(COMPLETED)
Phase 2
Completed
- Conditions
- Flushing
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 154
- Registration Number
- NCT00536237
MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)
Phase 2
Completed
- Conditions
- Seasonal Allergies
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 766
- Registration Number
- NCT00533208
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath